



## Aetna Better Health of Texas PROVIDER NOTIFICATION

Dear Valued Provider,

In a periodic review of our Prior Authorization code listing, Effective July 1, 2025, Aetna Better Health of Texas **will require prior authorization** for the codes listed below for participating providers. The change applies to CHIP, STAR and STAR Kids. Codes remain non covered for CHIP Perinate. As always, do not hesitate to contact your Aetna Better Health of Texas Provider Relations Representative with any questions or comments.

Please refer to the provider pre-authorization tool for the most up to date listing of codes requiring a prior authorization

<https://www.aetnabetterhealth.com/texas/providers/prior-authorization.html>

**Please note: This new process may result in a change in how your practice is reimbursed for these services. We urge you to thoroughly review the information in this document and in the attached policy.**

### CHIP

#### Bexar area

1-866-818-0959 (TTY: 711)

#### Tarrant area

1-800-245-5380 (TTY: 711)

### STAR (Medicaid)

#### Bexar area

1-800-248-7767 (TTY: 711)

#### Tarrant area

1-800-306-8612 (TTY: 711)

### STAR Kids

#### Dallas and Tarrant areas

1-844-787-5437 (TTY: 711)

Thank you for your valued partnership in caring for our Aetna Better Health Members.

Sincerely,

Provider Services and Chief Medical Officer  
Aetna Better Health of Texas

### Code List

Code	Code Description
<b>38225</b>	Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day
<b>38226</b>	Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage)
<b>38227</b>	Chimeric antigen receptor T-cell (CAR-T) therapy; receipt and preparation of CAR-T cells for administration

<b>38228</b>	Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous
<b>51721</b>	Insertion of transurethral ablation transducer for delivery of thermal ultrasound for prostate tissue ablation, including suprapubic tube placement during the same session and placement of an endorectal cooling device, when performed
<b>55881</b>	Ablation of prostate tissue, transurethral, using thermal ultrasound, including magnetic resonance imaging guidance for, and monitoring of, tissue ablation;
<b>55882</b>	Ablation of prostate tissue, transurethral, using thermal ultrasound, including magnetic resonance imaging guidance for, and monitoring of, tissue ablation; with insertion of transurethral ultrasound transducer for delivery of thermal ultrasound, including suprapubic tube placement and placement of an endorectal cooling device, when performed
<b>60660</b>	Ablation of 1 or more thyroid nodule(s), one lobe or the isthmus, percutaneous, including imaging guidance, radiofrequency
<b>61715</b>	Magnetic resonance image guided high intensity focused ultrasound (MRgFUS), stereotactic ablation of target, intracranial, including stereotactic navigation and frame placement, when performed
<b>64466</b>	Thoracic fascial plane block, unilateral; by injection(s), including imaging guidance, when performed
<b>64467</b>	Thoracic fascial plane block, unilateral; by continuous infusion(s), including imaging guidance, when performed
<b>64468</b>	Thoracic fascial plane block, bilateral; by injection(s), including imaging guidance, when performed
<b>64469</b>	Thoracic fascial plane block, bilateral; by continuous infusion(s), including imaging guidance, when performed
<b>64473</b>	Lower extremity fascial plane block, unilateral; by injection(s), including imaging guidance, when performed
<b>64474</b>	Lower extremity fascial plane block, unilateral; by continuous infusion(s), including imaging guidance, when performed
<b>66683</b>	Implantation of iris prosthesis, including suture fixation and repair or removal of iris, when performed
<b>81195</b>	Cytogenomic (genome-wide) analysis, hematologic malignancy, structural variants and copy number variants, optical genome mapping (OGM)
<b>81558</b>	Transplantation medicine (allograft rejection, kidney), mRNA, gene expression profiling by quantitative polymerase chain reaction (qPCR) of 139 genes, utilizing whole blood, algorithm reported as a binary categorization as transplant excellence, which indicates immune quiescence, or not transplant excellence, indicating subclinical rejection

<b>82233</b>	Beta-amyloid; 1-40 (Abeta 40)
<b>82234</b>	Beta-amyloid; 1-42 (Abeta 42)
<b>83884</b>	Neurofilament light chain (NfL)
<b>84393</b>	Tau, phosphorylated (eg, pTau 181, pTau 217), each
<b>84394</b>	Tau, total (tTau)
<b>87513</b>	Infectious agent detection by nucleic acid (DNA or RNA); Helicobacter pylori (H. pylori), clarithromycin resistance, amplified probe technique
<b>87594</b>	Infectious agent detection by nucleic acid (DNA or RNA); Pneumocystis jirovecii, amplified probe technique
<b>90593</b>	Chikungunya virus vaccine, recombinant, for intramuscular use
<b>0521U</b>	Rheumatoid factor IgA and IgM, cyclic citrullinated peptide (CCP) antibodies, and scavenger receptor A (SR-A) by immunoassay, blood
<b>0522U</b>	Carbonic anhydrase VI, parotid specific/secretory protein and salivary protein 1 (SP1), IgG, IgM, and IgA antibodies, chemiluminescence, semiquantitative, blood
<b>0523U</b>	Oncology (solid tumor), DNA, qualitative, next-generation sequencing (NGS) of singlenucleotide variants (SNV) and insertion/deletions in 22 genes utilizing formalin-fixed paraffinembedded tissue, reported as presence or absence of mutation(s), location of mutation(s), nucleotide change, and amino acid change
<b>0524U</b>	Obstetrics (preeclampsia), sFlt1/PlGF ratio, immunoassay, utilizing serum or plasma, reported as a value
<b>0525U</b>	Oncology, spheroid cell culture, 11-drug panel (carboplatin, docetaxel, doxorubicin, etoposide, gemcitabine, niraparib, olaparib, paclitaxel, rucaparib, topotecan, veliparib) ovarian, fallopian, or peritoneal response prediction for each drug
<b>0526U</b>	Nephrology (renal transplant), quantification of CXCL10 chemokines, flow cytometry, urine, reported as pg/mL creatinine baseline and monitoring over time
<b>0527U</b>	Herpes simplex virus (HSV) types 1 and 2 and Varicella zoster virus (VZV), amplified probe technique, each pathogen reported as detected or not detected

<b>0528U</b>	Lower respiratory tract infectious agent detection, 18 bacteria, 8 viruses, and 7 antimicrobial resistance genes, amplified probe technique, including reverse transcription for RNA targets, each analyte reported as detected or not detected with semiquantitative results for 15 bacteria
<b>0529U</b>	Hematology (venous thromboembolism [VTE]), genome-wide single-nucleotide polymorphism variants, including F2 and F5 gene analysis, and Leiden variant, by microarray analysis, saliva, report as risk score for VTE
<b>0530U</b>	Oncology (pan-solid tumor), ctDNA, utilizing plasma, next generation sequencing (NGS) of 77 genes, 8 fusions, microsatellite instability, and tumor mutation burden, interpretative report for single-nucleotide variants, copy number alterations, with therapy association
<b>0906T</b>	Concurrent optical and magnetic stimulation (COMS) therapy, wound assessment and dressing care; first application, total wound(s) surface area less than or equal to 50 sq cm
<b>0908T</b>	Open implantation of integrated neurostimulation system, vagus nerve, including analysis and programming, when performed
<b>0909T</b>	Replacement of integrated neurostimulation system, vagus nerve, including analysis and programming, when performed
<b>0910T</b>	Removal of integrated neurostimulation system, vagus nerve
<b>0913T</b>	Percutaneous transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon (eg, drug-coated, drug-eluting), including mechanical dilation by nondrug-delivery balloon angioplasty, endoluminal imaging using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) when performed, imaging supervision, interpretation, and report, single major coronary artery or branch
<b>0915T</b>	Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; pulse generator and dual transvenous electrodes/leads (pacing and defibrillation)
<b>0916T</b>	Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; pulse generator only
<b>0917T</b>	Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; single transvenous lead (pacing or defibrillation) only
<b>0918T</b>	Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; dual transvenous leads (pacing and defibrillation) only
<b>0919T</b>	Removal of a permanent cardiac contractility modulation-defibrillation system component(s); pulse generator only
<b>0920T</b>	Removal of a permanent cardiac contractility modulation-defibrillation system component(s); single transvenous pacing lead only

<b>0921T</b>	Removal of a permanent cardiac contractility modulation-defibrillation system component(s); single transvenous defibrillation lead only
<b>0922T</b>	Removal of a permanent cardiac contractility modulation-defibrillation system component(s); dual (pacing and defibrillation) transvenous leads only
<b>0923T</b>	Removal and replacement of permanent cardiac contractility modulation-defibrillation pulse generator only
<b>0924T</b>	Repositioning of previously implanted cardiac contractility modulation-defibrillation transvenous electrode(s)/lead(s), including fluoroscopic guidance and programming of sensing and therapeutic parameters
<b>0925T</b>	Relocation of skin pocket for implanted cardiac contractility modulation-defibrillation pulse generator
<b>0926T</b>	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation-defibrillation system
<b>0927T</b>	Interrogation device evaluation (in person) with analysis, review, and report, including connection, recording, and disconnection, per patient encounter, implantable cardiac contractility modulation-defibrillation system
<b>0928T</b>	Interrogation device evaluation (remote), up to 90 days, cardiac contractility modulation-defibrillation system with interim analysis and report(s) by a physician or other qualified health care professional
<b>0929T</b>	Interrogation device evaluation (remote), up to 90 days, cardiac contractility modulation-defibrillation system, remote data acquisition(s), receipt of transmissions, technician review, technical support, and distribution of results
<b>0930T</b>	Electrophysiologic evaluation of cardiac contractility modulation-defibrillator leads, including defibrillation-threshold evaluation (induction of arrhythmia, evaluation of sensing and therapy for arrhythmia termination), at time of initial implantation or replacement with testing of cardiac contractility modulation-defibrillator pulse generator
<b>0931T</b>	Electrophysiologic evaluation of cardiac contractility modulation-defibrillator leads, including defibrillation-threshold evaluation (induction of arrhythmia, evaluation of sensing and therapy for arrhythmia termination), separate from initial implantation or replacement with testing of cardiac contractility modulation-defibrillator pulse generator
<b>0932T</b>	Noninvasive detection of heart failure derived from augmentative analysis of an echocardiogram that demonstrated preserved ejection fraction, with interpretation and report by a physician or other qualified health care professional
<b>0933T</b>	Transcatheter implantation of wireless left atrial pressure sensor for long-term left atrial pressure monitoring, including sensor calibration and deployment, right heart catheterization, transseptal puncture, imaging guidance, and radiological supervision and interpretation
<b>0934T</b>	Remote monitoring of a wireless left atrial pressure sensor for up to 30 days, including data from daily uploads of left atrial pressure recordings, interpretation(s) and trend analysis, with adjustments to the diuretics plan, treatment paradigm thresholds, medications or lifestyle modifications, when performed, and report(s) by a physician or other qualified health care professional

<b>0935T</b>	Cystourethroscopy with renal pelvic sympathetic denervation, radiofrequency ablation, retrograde ureteral approach, including insertion of guide wire, selective placement of ureteral sheath(s) and multiple conformable electrodes, contrast injection(s), and fluoroscopy, bilateral
<b>0936T</b>	PHOTOBIMODULATION THERAPY RETINA SINGLE SESSION
<b>0937T</b>	External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; including recording, scanning analysis with report, review and interpretation by a physician or other qualified health care professional
<b>0938T</b>	External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; recording (including connection and initial recording)
<b>0939T</b>	External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; scanning analysis with report
<b>0940T</b>	External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; review and interpretation by a physician or other qualified health care professional
<b>0941T</b>	Cystourethroscopy, flexible; with insertion and expansion of prostatic urethral scaffold using integrated cystoscopic visualization
<b>0942T</b>	Cystourethroscopy, flexible; with removal and replacement of prostatic urethral scaffold
<b>0943T</b>	Cystourethroscopy, flexible; with removal of prostatic urethral scaffold
<b>0944T</b>	3D contour simulation of target liver lesion(s) and margin(s) for image-guided percutaneous microwave ablation
<b>0946T</b>	Orthopedic implant movement analysis using paired computed tomography (CT) examination of the target structure, including data acquisition, data preparation and transmission, interpretation and report (including CT scan of the joint or extremity performed with paired views)
<b>0947T</b>	Magnetic resonance image guided low intensity focused ultrasound (MRgFUS), stereotactic blood-brain barrier disruption using microbubble resonators to increase the concentration of blood-based biomarkers of target, intracranial, including stereotactic navigation and frame placement, when performed
<b>A9615</b>	Injection, pegulicianine, 1 mg
<b>C1737</b>	Joint fusion and fixation device(s), sacroiliac and pelvis, including all system components (implantable)
<b>C7562</b>	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed with intraprocedural coronary

	fractional flow reserve (ffr) with 3d functional mapping of color-coded ffr values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention
<b>C7563</b>	Transluminal balloon angioplasty (except lower extremity artery(ies) for occlusive disease, intracranial, coronary, pulmonary, or dialysis circuit), open or percutaneous, including all imaging and radiological supervision and interpretation necessary to perform the angioplasty within the same artery, initial artery and all additional arteries
<b>C8001</b>	3d anatomical segmentation imaging for preoperative planning, data preparation and transmission, obtained from previous diagnostic computed tomographic or magnetic resonance examination of the same anatomy
<b>C8002</b>	Preparation of skin cell suspension autograft, automated, including all enzymatic processing and device components (do not report with manual suspension preparation)
<b>C8003</b>	Implantation of medial knee extraarticular implantable shock absorber spanning the knee joint from distal femur to proximal tibia, open, includes measurements, positioning and adjustments, with imaging guidance (eg, fluoroscopy)
<b>C9173</b>	Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram
<b>C9804</b>	Elastomeric infusion pump (e.g., on-q* pump with bolus), including catheter and all disposable system components, non-opioid medical device (must be a qualifying medicare non-opioid medical device for post-surgical pain relief in accordance with section 4135 of the caa, 2023)
<b>C9806</b>	Rotary peristaltic infusion pump (e.g., ambit pump), including catheter and all disposable system components, non-opioid medical device (must be a qualifying medicare non-opioid medical device for post-surgical pain relief in accordance with section 4135 of the caa, 2023)
<b>C9807</b>	Nerve stimulator, percutaneous, peripheral (e.g., sprint peripheral nerve stimulation system), including electrode and all disposable system components, non-opioid medical device (must be a qualifying medicare non-opioid medical device for post-surgical pain relief in accordance with section 4135 of the caa, 2023)
<b>C9808</b>	Nerve cryoablation probe (e.g., cryoice, cryosphere, cryosphere max, cryoice cryosphere, cryoice cryo2), including probe and all disposable system components, non-opioid medical device (must be a qualifying medicare non-opioid medical device for post-surgical pain relief in accordance with section 4135 of the caa, 2023)
<b>C9809</b>	Cryoablation needle (e.g., iovera system), including needle/tip and all disposable system components, non-opioid medical device (must be a qualifying medicare non-opioid medical device for post-surgical pain relief in accordance with section 4135 of the caa, 2023)
<b>E1803</b>	Dynamic adjustable elbow extension only device, includes soft interface material
<b>E1804</b>	Dynamic adjustable elbow flexion only device, includes soft interface material
<b>E1807</b>	Dynamic adjustable wrist extension only device, includes soft interface material
<b>E1808</b>	Dynamic adjustable wrist flexion only device, includes soft interface material

<b>E1813</b>	Dynamic adjustable knee extension only device, includes soft interface material
<b>E1814</b>	Dynamic adjustable knee flexion only device, includes soft interface material
<b>E1822</b>	Dynamic adjustable ankle extension only device, includes soft interface material
<b>E1823</b>	Dynamic adjustable ankle flexion only device, includes soft interface material
<b>E1826</b>	Dynamic adjustable finger extension only device, includes soft interface material
<b>E1827</b>	Dynamic adjustable finger flexion only device, includes soft interface material
<b>E1828</b>	Dynamic adjustable toe extension only device, includes soft interface material
<b>E1829</b>	Dynamic adjustable toe flexion only device, includes soft interface material
<b>G0552</b>	Supply of digital mental health treatment device and initial education and onboarding, per course of treatment that augments a behavioral therapy plan
<b>G0553</b>	First 20 minutes of monthly treatment management services directly related to the patient's therapeutic use of the digital mental health treatment (dmht) device that augments a behavioral therapy plan, physician/other qualified health care professional time reviewing information related to the use of the dmht device, including patient observations and patient specific inputs in a calendar month and requiring at least one interactive communication with the patient/caregiver during the calendar month
<b>G0554</b>	Each additional 20 minutes of monthly treatment management services directly related to the patient's therapeutic use of the digital mental health treatment (dmht) device that augments a behavioral therapy plan, physician/other qualified health care professional time reviewing data generated from the dmht device from patient observations and patient specific inputs in a calendar month and requiring at least one interactive communication with the patient/caregiver during the calendar month
<b>G0555</b>	Provision of replacement patient electronics system (e.g., system pillow, handheld reader) for home pulmonary artery pressure monitoring
<b>G0561</b>	Tympanostomy with local or topical anesthesia and insertion of a ventilating tube when performed with tympanostomy tube delivery device, unilateral (list separately in addition to 69433) (do not use in conjunction with 0583t)
<b>G0563</b>	Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance and real-time positron emissions-based delivery adjustments to 1 or more lesions, entire course not to exceed 5 fractions

<b>G0564</b>	Creation of subcutaneous pocket with insertion of 365 day implantable interstitial glucose sensor, including system activation and patient training
<b>J0139</b>	Injection, adalimumab, 1 mg
<b>J0605</b>	Sucroferric oxyhydroxide, oral, 5 mg (for esrd on dialysis)
<b>J0607</b>	Lanthanum carbonate, oral, 5 mg (for esrd on dialysis)
<b>J0608</b>	Lanthanum carbonate, oral, powder, 5 mg, not therapeutically equivalent to j0607 (for esrd on dialysis)
<b>J0609</b>	Ferric citrate, oral, 3 mg ferric iron, (for esrd on dialysis)
<b>J0870</b>	Injection, imetelstat, 1 mg
<b>J0901</b>	Vadadustat, oral, 1 mg (for esrd on dialysis)
<b>J1307</b>	Injection, crovalimab-akkz, 10 mg
<b>J1414</b>	Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose
<b>J1552</b>	Injection, immune globulin (alyglo), 500 mg
<b>J2472</b>	Injection, pantoprazole sodium in sodium chloride (baxter), 40 mg
<b>J2802</b>	Injection, romiplostim, 1 microgram
<b>J3392</b>	Injection, exagamglogene autotemcel, per treatment
<b>J7601</b>	Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mg
<b>J9026</b>	Injection, tarlatamab-dlle, 1 mg

<b>J9028</b>	Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram
<b>J9076</b>	Injection, cyclophosphamide (baxter), 5 mg
<b>J9292</b>	Injection, pemetrexed (avyxa), not therapeutically equivalent to j9305, 10 mg
<b>Q0155</b>	Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
<b>Q4346</b>	Shelter dm matrix, per square centimeter
<b>Q4347</b>	Rampart dl matrix, per square centimeter
<b>Q4348</b>	Sentry sl matrix, per square centimeter
<b>Q4349</b>	Mantle dl matrix, per square centimeter
<b>Q4350</b>	Palisade dm matrix, per square centimeter
<b>Q4351</b>	Enclose tl matrix, per square centimeter
<b>Q4352</b>	Overlay sl matrix, per square centimeter
<b>Q4353</b>	Xceed tl matrix, per square centimeter
<b>Q5139</b>	Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mg
<b>Q5140</b>	Injection, adalimumab-fkjp, biosimilar, 1 mg
<b>Q5141</b>	Injection, adalimumab-aaty, biosimilar, 1 mg
<b>Q5142</b>	Injection, adalimumab-ryvk biosimilar, 1 mg

<b>Q5143</b>	Injection, adalimumab-adbm, biosimilar, 1 mg
<b>Q5144</b>	Injection, adalimumab-aacf (idacio), biosimilar, 1 mg
<b>Q5145</b>	Injection, adalimumab-afzb (abrilada), biosimilar, 1 mg
<b>Q5146</b>	Injection, trastuzumab-strf (hercessi), biosimilar, 10 mg
<b>Q9996</b>	Injection, ustekinumab-ttwe (pyzchiva), subcutaneous, 1 mg
<b>Q9997</b>	Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg
<b>Q9998</b>	Injection, ustekinumab-aekn (selarsdi), 1 mg